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This risk management project aims to apply a global preventive and predictive measure in
potential victims of acute death and heart failure. Among the main causes are identiﬁed
sub-diagnosed genetic mutations; prescription, interaction, self-medication or abuse of
suspected drugs due to internet prospect's consult; and a parasitic pandemia, the Chagas
disease (over 100000000 population is potentially infected worldwide). Promoting a
global extensive determination of the torsadogenic index which was successfully pub-
lished in Frontiers of Pharmacology Journal, will allow to monitor general population, set
security patterns to categorize silent high risk groups of serious prognosis of tachyar-
rhythmias. For this purpose, applications of known QT determinations are proposed,
recommending Dr. Rautaharju's formula, actually improved with gender adult versions.
Torsadogenic index will allow to establish an individual traceability, obtain comparative
samples that are alert to possible QT enlargements. Thus, torsadogenic index results a
valuable, simple and costless resource to consider in the ﬁght against acute death and
cardiac arrest. Torsadogenic index represents a global indicator capable of predicting and
preventing acute death and heart failure for most relevant reasons.1. Introduction
Torsadogenic index allows the evaluation of QT enlarge-
ment, transforming itself into a preventive-predictive instrument
for acute death and heart arrest for various reasons.
According to record of paper downloads in Frontiers of
Pharmacology Journal during 2012–2013, torsadogenic index is
a proposal to improve survival rates in cardiac arrests due to
prescribed drugs and required as theme for session speaking
during the International Drug Discovery Congress in Dubai and
in the World Discovery Congress in Boston[1]. Torsadogenic
index deserves to be proposed as a contingency strategy into a
risk management project (ISO FDIS 31000: 2009 compliance),
in order to mitigate the probability of its occurrence and death
risk impact, as well as to avoid the materialization of these
issues due to them[2].
It might seem an ambitious attempt to cover in one work
different genetic mutations, torsadogenic drugs and a global
endemic parasitosis. However, it happens that all of them
converge into identical dangers, consequences and efforts toestablish safeguards that involve simple and very low cost
determinations.1.1. Project risk goals (ISO FDIS 31000: 2009)
Therefore, it is imperative to establish the objectives of the
aforementioned project, based upon the following priorities, in
accordance with ISO FDIS 31000: 2009 standard[3]: (a) Risk
identiﬁcation to minimize issue's probability of occurrence; (b)
Risk project analysis; (c) Risk monitoring until issues'
disappearance; (d) Risk project control.
Understanding that meeting these goals is the optimal way of
avoiding risks through the implementation of this International
Standard; it is mandatory to propose a risk management process
adapted to any kind of situation leading to conditions involving
potential danger which may result in a Torsade de Pointes (TdP)
and subsequent cardiac arrest.
This is the main basis for coupling a standard risk manage-
ment to achieve the objective of safeguards proposed in this
project.
1.2. Risk management process (ISO FDIS 31000: 2009)
Both ISO 9001: 2008 and ISO 31000: 2009 provide prin-
ciples and generic guidelines on project and risk management
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risks[3,4].
The proposed quality model is presented in the Figure 1.
We will follow this ‘logical stream of intervention’, in order
to achieve success in our management through ISO standards.
2. Methodological approach: torsadogenic index's
risk management process cyclic sequence
Now we will start to break down, step by step, each statement
that involves the proposed process.
2.1. Torsadogenic index risk project evaluation (ISO
FDIS 31000: 2009)
We will address together the sequence of this project for top
convergent conditions around this problem: genetic mutations,
drugs and Chagas disease. The foregoing sets forth TdP as a
preliminary step to ventricular ﬁbrillation, a major cause of heart
arrest.
2.2. Torsadogenic index risk project statements (ISO
FDIS 31000: 2009)
(1) Risk identiﬁcation; (2) risk probability and impact anal-
ysis; (3) risk control (for its negative, collateral or residual ef-
fects); (4) risk status and results (from handling and/or
monitoring actions).
An expectable consequence of maintaining a strict and
continuing surveillance through the presented sequence in the
above project could result in a marked reduction of the sub-
diagnosed cases of genetic mutations, in an unnecessary with-
drawal from the market of suspected drugs and a controlled
intervention over treated and potentially infected patients with
Chagas disease.
This would make it possible to extend preventive measures to
these risky pathological conditions, not only to those included inFigure 1. Risk management process.high risk groups (relatives of diagnosed cases of genetic muta-
tions, relatives of victims of sudden death or cardiac arrest,
contacts or relatives of patients treated for Chagas disease) but
also to all the people in general, broadening the spectrum for
identifying the presented conditions, proposing the same indi-
cator to be also used as screening and follow-up tracer in newly
discovered cases.
2.3. Risk project identiﬁcation (ISO FDIS 31000: 2009)
While considering together these potential threats converging
towards this project's implementation, we will evaluate and
analyze each condition separately, in order to try to elucidate
their mechanisms of action that allow us to identify them.
Regarding long QT syndrome (LQTS), it is a sarcolemmic
intracellular ion channel dysfunction in the cardiac cell mem-
brane by speciﬁc genes that regulate cardiomyocyte's potas-
sium entry and are responsible for sine materia sudden
deaths[5,6].
According to the worldwide recognized cardiology expert,
Peter Schwartz, “The basic defect in LQTS is an unknown
intracardiac abnormality that decreases electrical stability and
makes the myocardium more vulnerable to the effect of sym-
pathetic discharges[7].” The quoted situation may trigger a
ventricular tachyarrhythmia that, in these patients, could
directly lead to death. This risk is inﬂuenced by various
causes: gender, genotype, exposure to triggers and history of
previous events.
2.3.1. Statistical analysis of involved hazards
The above mentioned condition could also appear after
congenital mutations (congenital LQTS) or for other secondary
reasons (acquired LQTS)[7].
2.3.2. Congenital long QT inherited genetic syndromes
This group can be sub-divided into different types Table 1
[9,10].
Table 2
Genetic determinants: 3 most important variations[10].
Genetic
determinants
Variations Percentage
(%)
LQTS 1
(9 years-old)
Chromosome 11 KCNQ1 63
LQTS 2
(12 years-old)
Chromosome 7 KCNH2 (Herg) 35
LQTS 3
(16 years-old)
Chromosome 3 SCN5A
(Brugada subtype 1)
1
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there are many genotype variations, there are three most
important conditions as genetic determinants: LQTS 1, LQTS 2
and LQTS 3 (Table 2).
According to Wu et al., the most frequent type of congenital
long QT syndrome is LQTS1 (more than 50% of the cases),
which is caused by mutations in the KCNQ1 gene that encodes
alpha-subunit of the slow component of delayed rectiﬁer K+
(Iks) major repolarizing current[10]. However, they discovered
that at least 13 genes were responsible for different subtypes
of the syndrome[10].
Dr. Schwartz warns us that neither the localization of a
mutation nor its cellular electrophysiological effect could be
enough to consistently unmask the presence and severity of
mutation carriers LQT1 and predict the impact on their clinical
manifestations[7]. As he claimed, “a borderline-normal QT may
still be associated with severe risk of arrhythmia, as postulated
long ago[7].” Schwartz, PJ: The long QT syndrome[11].
In acquired LQTS, there are also genetic conditioners grav-
itating over these genetic syndromes, like CVP2D6 gene, and
locus manifestation for cytochrome P450, which affects catalytic
enzyme to metabolize drugs and toxics in 5%–10% of the
Caucasian population.
According to Dr. Jufeng Wang, ex-chief science ofﬁcer of
Explorative Toxicological Assessment for Consumer Products in
Harvard and current director of the Chinese National Drug
Evaluation Center, “nearly 47% of LQTS has a congenital
origin[12].” For this reason, we will necessarily be forced to
identify and analyze the rest of the causes to try to stem the
probability of impact which may lead to the same result, and
ultimately, the cardiac arrest.
Thanks to his contribution, current Pharmacological Regu-
latory Committees identiﬁed sentinel effects of drugs already
placed on the market.
Dr. Wang informed in 2010 that 1.5 million people required
hospitalization and 100000 died due to those TdP causing drugs,
and situation that is the consequence of (1) inadequate drugTable 1
Congenital long QT inherited genetic syndromes (1/5000 cases).
Subgroups of congenital long QT syndromes
- Jervell and Lange-Nielsen Syndrome (Oslo – associated with
central deafness)
Chromosome 11 – JLN1
Chromosome 21 – JLN2
- Romano – Ward Syndrome (Carlos Romano – O. Conor Ward)
Autosomic dominant form
Recessive form: Silvia Priori's Syndrome (1998)
- Benito Brugada's Syndrome[8] (1992)
 Brugada subtype 1: sudden infant death syndrome – SIDS –
SNC5A Gene
*Affection of slow late output rectiﬁer potassium channel
 Brugada subtype 2: AVR sign (Eduardo Schapachnik)
Channelopathy in right ventricular output
*Rapid potassium output channel disorder (phase 3)
(ST greater than or equal to 2 mm + positive or subphasic wave)
 Brugada subtype 3: sudden unexplained death syndrome –
SUDS
*Delayed sodium entry channel dysfunction (phase 2)
(Sudden death in south-east Asian young men?):
Bangungot (Philippines) Pokkuri (Japan) Lai Tai (Thailand)
‘Evil’ polymorphic ventricular tachycardia – catecholaminergic
ventricular tachycardia
(ST > 1 mm)prescription; (2) inadequate pharmacological interactions; and
(3) self-medication or abuse of torsadogenic drugs.
All of them resulted from the unfortunate consequences of a
lack of responsible cardiac surveillance of sentinel effects[13].
The above referred number climbed dramatically in 2012,
when Colorado, Utah and New York Studies Summary Reviews
estimated 198000 cases of drug adverse effects (almost the
double than in 2010) were registered and associated with
death[14].
That evidences an unstoppable progression of the increasing
mortality rate to truly catastrophic numbers by the end of this
present decade (from 16 to 18000000 deaths in 2014 to
30000000 cardiovascular victims in 2020)[15].
In Table 3, pharmacological causes are shown in the listed
causes of acute death. The drugs and their pharmacological
causes of ‘acute death’ can be seen, together with the conse-
quences arising there from. For other drugs with potential
to cause QT prolongation, it is available at: www.qtdrugs.org
or the First Worldwide Internet Symposium on drug-induced
QT prolongation at http://www.lqts-symposium.org/2007/
home.php.
As for the acquired LQTS, several causes are listed. Specif-
ically regarding the quoted cases leading to TdP, and both drugs
and Chagas disease are cited in Table 4.Table 3
Acute death's causes (American Colleague of Physicians).
Cause Manifestation
Cardiac causes Atrial ﬁbrillation
Cardiac tamponade
Aortic dissection or rupture
Arrhythmia infectological cases
Cardiac ﬁbroelastosis
Vascular causes Traumatic loss of blood
Spontaneous internal hemorrhage
Gut rupture
Anthrax
Clostridium perfringens
Colibacillosis
Pharmacological causes Intravenous injection (inappropriate
solutions)
Intravenous injection (too rapidly):
-Cardiac arrest
-Pulmonary edema
-Anaphylactic shock
-Idiosyncratic reactions
-Artiﬁcial poisons
-Natural poisons:
inadequate prescription, interaction,
abuse or self-indicated Tdp drugs
Others Electrocution
Lightning injury
Table 4
Acquired LQTS causes[6].
Cause Speciﬁcation
Metabolic abnormalities Hypothyroidism,
hyperparathyroidism,
pheochromocytoma
Antiarrhythmic drugs Class 1A: quinidine, procainamide,
disopyramide
Class 1C: ﬂecainide
Class 3: amiodarone, ibutilide
Central nervous system injury Subarachnoid hemorrhage, thalamic
hematoma, stroke, encephalitis,
head trauma
Other Electrolyte disturbances
Poisoning (arsenic, phosphorus
organs)
Malnutrition (anorexia nervosa,
liquid protein diets)
Peripheral nervous system
(autonomic neuropathy, HIV)
Brady arrhythmias Sinus arrhythmia
Sinus bradycardia
Chagas-Mazza disease
Atrioventricular block
Figure 2. Triple constraint.
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those of Class 1A (quinidine, procainamide, disopyramide),
Class 1C (ﬂecainide) or Class 3 (amiodarone, ibutilide), have
been attributed, in many cases, disastrous consequences that lead
to TdP.
Chagas-Mazza disease is endemic in Argentina. This is
consistent with epidemiological information that more than 10%
of the affected population, about 4000000 patients are currently
under treatment, extending to over 10000000 potentially
infected[16].
In case of South America, the ﬁgure reaches 34 million
infected; and current estimates calculate the number at
100000000 infected worldwide.
About this parasitic pandemics, although it is postulated
within the acquired LQTS, it also gets involved in genetic de-
terminants. Even though the pathophysiological mechanism of
cardiac Chagas-Mazza disease features QT interval dysauton-
omy and dispersion which result in chronotropic incompetence
at high heart rates (even without symptoms), there are evidences
of Gen 4 changes that are determinants of sinus bradycardia and
consequent LQTS.
Protein B-2, also called ankyrin, is an acquired mutation over
Gen 4 which involves preventive implant deﬁbrillator in 23% of
the patients or inappropriate therapies to cardioversion therapies
in 36% of treated chagasic disease each year[17].
As you can see, even among the presented pathological
conditions, there is a complex interplay of factors that determine
them intrinsically.
2.4. Torsadogenic index risk project's probability and
impact analysis (ISO FDIS 31000: 2009)
Risk analysis allows deductions from the project risk goals in
order to reduce their potential danger[2].
After identifying the risk, you will also need to determine (1)
risk probability of occurrence; (2) risk impact (magnitude of
loss); (3) risk exposure (magnitude of the real global threat).
Having presented the information contained in the previous
risk evaluation and identiﬁcation steps, we are able to state theabove mentioned risk which is in the absence of preventive or
contingency measures, will continue to rise inexorably.
We will seek to describe each of the risk analysis items
recently cited above.
2.4.1. Risk probability of occurrence (ISO FDIS 31000:
2009)
It speciﬁes the real possibility for a quoted risk to turn into an
issue[2].
Concerning the information about the lethal side effects of
torsadogenic drugs, based upon the previously presented data
obtained from USA studies, the mortality rates have increased
nearly 100% in only 2 years (100000 cases in 2010 and 198000
reported cases in 2012)[2,14].
At present, there is no consideration for genetic studies to
turn compulsory tests, so we have no objective information
regarding the particular; there are only indirect registered data
concerning mortality rates of acute death and cardiac arrest,
which are on the rise[7].
To make matters worse, our country has excluded Chagas
determination prior to labor admission due to the fact that it
is considered “access to employment discrimination” by
institutions governing the Ministry of Labor and Human
Rights.
In other words, only victims are recorded in data, and
there is no even an approximate knowledge about the po-
tential carriers of genetic mutations for patients or relatives of
victims with acute death and cardiac arrest; and luckily, those
who are taking suspected drugs are properly controlled during
treatment[7].
2.4.2. Risk impact
This is an indicator for measuring the extent of loss caused by
a risk[2,18].
In a “triple constraint” concept, it is determined by three
variables: cost, time and quality (Figure 2).
We will clarify each of these proposed triple constraint var-
iables, available in all project management[18]:
Time: the torsadogenic index could be applied immediately
to anyone and everywhere.
Cost: the torsadogenic index presupposes an easy imple-
mentation that implies zero cost.
Quality: Here we can consider this variable as “life-quality”,
by avoiding secondary or residual risk sequels (central nervous
system lesions; neurological impairments, etc.) due to cardiac
arrest.
2.4.3. Risk exposure
This indicator relates to the probability of occurrence to risk
impact[2].
Figure 4. Dr. Pentti M. Rautaharju's new QT index formula.
Figure 5. Dr. Pentti M. Rautaharju's new improved QT index formulas for
adult men and women.
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risk identiﬁcation step and the following statements in the tor-
sadogenic conditions analyzed in this work:
Although there are biochemical tests available for an early
diagnosis of genetic mutations, it is not agreed as a compulsive
practice by way of land in general population yet. This allows us
to understand the existence of a large number of sub-diagnosed
cases where it is not possible to deploy the aforementioned
project[7].
Despite of the spontaneous or induced drug withdrawal from
the market, risk exposure is yet high (vide supra USA studies)
and it will increase in the next years if current existing drugs are
still without a 10-year follow-up of true warnings of sentinel or
dangerous side effects. There is a growing trend towards self-
medication within the general population, which has now been
adversely impaired due to widespread computers with free ac-
cess to pharmacological prospect content[2,14].
Although Chagas disease is liable to be controlled through
epidemiological sanitary general disclosure, it is not possible to
prevent it through an extensive immunological protection de-
vice, as a vaccine would. For this reason, the WHO considered
the Chagas-Mazza disease within the world's top thirteen
neglected tropical diseases.
The quoted evaluation of risk exposure enables us to
consolidate a risk diagnosis in the process of establishing an
appropriate risk planning strategy.
2.5. Torsadogenic index risk management planning
(operational strategy) (ISO FDIS 31000: 2009)
As it was introduced in the Boston World Drug Discovery
Congress, the torsadogenic index risk strategy involves the
following ISO FDIS 31000: 2009 steps[3]: (1) establishing a risk
scale; (2)diagnosing risk status; (3) providing solutions
containing major risks; (4) cost-threat balance for proper risk
management; (5) risk management selection according to
exposure (vide supra); (6) risk action plan deﬁnition.
The QTc and QTp are predictive clues to diagnose TdP.
The torsadogenic index sets alarm guidelines based on QT
formulas in Figure 3 (Ex. Rautaharju) to determine the risk prior
to prescription of suspected drugs.
According to the author of this formula, Dr. Pentti M. Rau-
taharju, the latest improvements and modiﬁcations have been
made by their own creator, in order to enhance the accuracy of
the obtained data. By this way, a new formula, QT index, is
presented.
Here, I transcribe the words he has sent me:
“I have substantially expanded my search for simple, best
possible clinically practical formulas for the evaluation of QT
prolongation. I have succeeded in deriving formulas for QTFigure 3. Dr. Pentti M. Rautaharju's QTp formula.adjustment large well documented normal clinical trials and
community-based population groups. These new formulas
work better than the old QT index in older age groups and
over a wide range of heart rates, and still maintain the
simplicity of the old QT index”.
This new value, QT index, is a more precise version of Dr.
Rauraharju's old formula. Its calculation sequence is presented in
Figure 4.
In his own words, Dr. Rautaharju concluded his explanation
clarifying the practical simplicity of the proposed methodology:
“To summarize brieﬂy and to give you an idea about these new
formulas, the calculations required with a simple hand-held
calculator are as follows” (Figure 5).
2.6. Torsadogenic index risk monitoring and control
(ISO FDIS 31000: 2009)
Risk monitoring and control involves (1) continuous anal-
ysis and monitoring performance of identiﬁed risks; (2)
monitoring new collateral or residual risks; (3) maintaining
new potential or residual risks; (4) permanent contingency plan
revision; (5) risk mitigation by modiﬁcations of previous plans;
(6) effective assessment of the risk through responsible quality
performance.
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and monitoring will lead to positive outcomes in managing risk
of acute death and cardiac arrest.
2.7. Torsadogenic index safeguard against risk (ISO
FDIS 31000: 2009)
Mandatory registration of torsadogenic index prior to TdP
risk drug prescription allows an adequate monitoring and back-
up of this risk management process.
Pe´rez Riera et al., have suggested systematic electrocardi-
ography to trace the relatives of victims with congenital LQTS.
They agree to consider “the best diagnostic and prognostic
parameter in relatives of patients with congenital LQTS”[8].
Thus, posed objectives for this risk management project will
be achieved to upgrade the survival rates in acute death and heart
arrest.
Milestones related to torsadogenic index are as following: (1)
identiﬁcation of high risk population (congenital or acquired
LQTS); (2) electrocardiogram tests or analysis of possible early
warning signs of TdP; (3) electrocardiogram and torsadogenic
index screening during treatment (enhancement of timely de-
cisions for positive effects); (4) careful assessment of TdP drugs
through torsadogenic index, previewing occurrence probability
of side effect[2].
Favorable consequences derived from the global application
of the quoted indicator may lead to the following results: (1)
effective evaluation of proposed contingency measures; (2)
corrective actions based upon previous measures; (3) alternative
strategies available to face new risks; (4) extended contingency
plans over other stages of cardiac arrests; (5) risk management
plan to improve data registration accuracy; (6) unexpected effect
observations to allow taking new preventive measures, as well as
avoiding new risks.
3. Discussion
The present proportion of drug collateral effects is rising
from 50% to 70%. American College of Physicians judged “half
of them to be preventable”, but it is not clear whether the authors
based their estimate on a real number of victims, or on a sub-
jective assessment of the entire body of cases[14].
This was supported by the hierarchic opinion of Dr. Jufeng
Wang, current President of Food and Drug Administration,
China and Director of the National Chinese Drug Evaluation
Center, “… more than 51% of pharmacological medical prod-
ucts have severe collateral effects after their inclusion in the
commercial market.”
As for those tests referred to congenital conditions, such as
homogentisic acid and metabolic errors that require an early
diagnosis, the torsadogenic index must be included into newborn
compulsory tests, thus identifying nearly 50% of the total LQTS
cases.
Cardiologist expert Peter Schwartz wrote his latest paper for
the American College of Cardiology Foundation, and in his
section of “Pitfalls and limitations of genetic testing”, he
expressed his doubt in this way[19]:
“The methods to identify mutations are not 100% sensitive
and therefore a negative genetic test cannot exclude the dis-
order by itself. There remain a substantial number of cases
with classic symptoms and signs for one of the heritablearrhythmia syndromes which is negative for the many known
genes … Certain types of mutations can be missed by stan-
dard testing exercises[19].”
The above written absolutely coincides with what was stated
by Wu in this work:
“Lethal arrhythmias can occur in these apparently healthy
silent mutation carriers without any premonitory sign[10]”.
Wu et al. identiﬁed that, referring to LQTS1, those cases with
mutations over KCNQ1, G269S gene were heterozygous, and
remained asymptomatic with their resting QTc intervals ranging
from normal to borderline. However, they showed an excessive
QT prolongation during exercise, triggering cardiac events
during adrenergic stimulation. According to this study, these
patients had lengthy QTc intervals after exercise[10].
Regarding Chagas-Mazza disease, it must be remembered
that there is no vaccine or preventive medication available for
this parasite, and further conventional treatment does not elim-
inate the disease, except for recent experimental results attrib-
uted to posaconazole, an antifungal of high cost in our
country[20].
The torsadogenic index risk management project goals
imply the development of promptly practical and costless se-
curity measures which will allow the prevention of possible
severe cardiac conditions and lead to consider the Torsado-
genic index as a preventive-predictive method, which is able to
turn acute death prognosis into a preventable and predictable
condition.
Expectable consequences of the torsadogenic risk manage-
ment project will result in (1) improving pharmacological
avoidable mortality; (2) upgrading cardiac arrest survival rates;
(3) improving active cardio-safety preventive care; (4) promptly
achieving practical-costless security.
Knowing in advance unrecognized acute death causes, and
activating undiagnosed diseases interception before the appear-
ance of lethal complications is very important.
Thus, a preventable death risk mitigation planning will help
to discover unexpected causes prior to their extremely severe
transformation.4. Conclusions
With respect to the goals of this risk management project, the
development of promptly practical and costless security mea-
sures to avoid severe cardiac conditions will help to consider the
torsadogenic index as a preventive-predictive method that is
capable of changing acute death prognosis.
Prescription and drug interaction stand as the fourth leading
cause of death in USA with nearly 300000 victims per year[21].
Regarding the risk impact, the torsadogenic index could
dramatically impair the occurrence likelihood of TdP, reducing
the risk before waiting its dangerous conversion into an issue.
Particularly referring to the pharmacological causes, inad-
equate prescription, interactions, self-medication or abuse of
torsadogenic drugs recognize an annual current hospital
admission of drug adverse effects of 2.9%–3.7% of overall
hospital admission. So, American College of Physicians stated
it as “… over half of those adverse events resulting from
medical errors”, meaning that quoted percentages can be efﬁ-
ciently prevented.
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agement planning will turn this danger into a preventable mea-
sure over medical or pharmacological failures, avoiding fatal
consequences due to inadequate drug prescription or combina-
tion, and thus improving the present health care possibility of
changing these circumstances that frequently lead to death.
The deduction that may emerge from reading the aforemen-
tioned experts in LQTS and genetic mutations makes us
conclude that, although the possibility of genetic registry rep-
resents a breakthrough for proper control of this problem, it
could be realized that there are some cases in which, despite
having referral genetic traits, they will never suffer from acute
death or cardiac arrest, or, conversely, may die without the
manifestations of LQTS genetics[20]. Therefore, genetic testing
does not seem to constitute itself the solution to the problem
of LQTS mutation.
In the words of the cardiologist Peter Schwartz: “the inter-
pretation of a negative genetic test result in a symptomatic
person is a real challenge. Therefore, interpreting genetic test
results is often confounded by the discovery of variants of un-
known signiﬁcance.”
In his extended study, Wu suggested that patients with
G269S mutations and an excessive prolongation of QT intervals
could beneﬁt from beta-blocker therapy.
Therefore, continuous efforts must be made to identify them
properly[10].
In his masterful work, Dr. Morillo CA emphasized medico-
legal implications and the balance between the conﬁdentiality
of observation data and the duty to report and follow-up patients
having tests with positive ﬁndings[20]:
“Likewise, the physician who, after having obtained positive
genotyping, and does not propose to initiate cascade
screening within the family of the proband, has similarly fully
decided to leave the affected family members uninformed
about their status and unprotected”.
Given the severity of all the nosological situations presented
in this work, I guess the same consideration should be already
extended for suspicious drugs, Chagas disease and to all other
diagnostic attempts to safeguard the patients, by identifying their
pathological conditions to enable timely medical intervention.
The torsadogenic index, with its simplicity and low-cost
implementation, should not be the exception to this rule.
Despite of this, Human Right's Defense and International
Regulations poses our professional duty to provide full infor-
mation to patients. Our commitment of a responsible risk
assessment “… is the prevention of serious consequences of
these diseases, and the respect of equal human rights, ensuring
that all newborns have an access to an early diagnosis, pre-
venting, thus death or disability for life”, according to Dr.
Magdalena Ugarte, Director of Center of Molecular Disease
Diagnosis, Department of Biochemistry and Molecular Biology,
Universidad Auto´noma de Madrid[22].
In this way, supporting the torsadogenic index risk man-
agement planning will be considered another predictable and
preventable measure over medical and pharmacological failures,
by avoiding fatal consequences due to inadequate drug pre-
scriptions or combinations, and improving actual medical pos-
sibilities of changing the circumstances that lead to death for all
these reasons.
Quoted as a mandatory record of contingency strategy, the
purpose of torsadogenic index risk management will maximizethe success of the project, thus preventing or mitigating risks
before they become real problems.
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